Literature DB >> 17592265

Clear cell adenocarcinoma associated with clear cell adenofibromatous components: a subgroup of ovarian clear cell adenocarcinoma with distinct clinicopathologic characteristics.

Sohei Yamamoto1, Hitoshi Tsuda, Tomoyuki Yoshikawa, Kazuya Kudoh, Tsunekazu Kita, Kenichi Furuya, Seiichi Tamai, Osamu Matsubara.   

Abstract

We occasionally encountered clear cell adenofibromatous (CCAF) components coexisting in the ovarian clear cell adenocarcinoma (CCA). To reveal the clinicopathologic significance of CCAF components in CCA, we classified 67 cases of surgically resected CCA into CCA with and without CCAF components [CCAF(+) and (-) groups], and compared clinicopathologic parameters, that is, patient age, clinical stage, the degree of optimal cytoreduction, patient outcome, histologic grade and Ki-67 labeling index of the CCA, and the presence of endometriosis, between these 2 groups. Fourteen cases (21%) and 53 cases were classified as CCAF(+) and CCAF(-) groups, respectively. Of these 14 CCAF(+) cases, the CCAF components with atypia were observed adjacent to the CCAF components without atypia in 10, and adjacent to the obvious CCAs in 13 cases. In comparison with the CCAF(-) group, the CCAF(+) group showed a higher frequency of histologically low-grade tumors [93% (13 of 14) vs. 43% (23 of 53), P=0.0027], a lower Ki-67 labeling index (mean 35.9% vs. 44.0%, P=0.0492), and better patient prognosis (5-year survival 78.8% vs. 49.3%, P=0.0277). Endometriosis was much less frequent in the CCAF(+) group than in the CCAF(-) group [14.7% (2 of 14) vs. 67.9% (36 of 53), P=0.00096]. Multivariate analysis identified only optimal cytoreduction as independent favorable prognostic factor. These results suggest that CCAF besides endometriosis is associated with the development of CCA, and that the CCAF(+) group may be a distinct subgroup of CCA with less aggressive biologic behavior.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17592265     DOI: 10.1097/01.pas.0000249449.13466.3c

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  10 in total

1.  PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.

Authors:  Sohei Yamamoto; Hitoshi Tsuda; Masashi Takano; Seiichi Tamai; Osamu Matsubara
Journal:  Virchows Arch       Date:  2011-11-26       Impact factor: 4.064

Review 2.  Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.

Authors:  Andrew Bryant; Shaun Hiu; Patience T Kunonga; Ketankumar Gajjar; Dawn Craig; Luke Vale; Brett A Winter-Roach; Ahmed Elattar; Raj Naik
Journal:  Cochrane Database Syst Rev       Date:  2022-09-26

3.  Primary Ovarian Clear Cell Adenofibroma of Borderline Malignancy.

Authors:  Ebru Cakir; Engin Aydin; Nılufer Imamoglu Durmus; Emine Samdanci; Nurhan Sahin; Zeynep Nurkabul
Journal:  Oman Med J       Date:  2012-01

4.  Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary.

Authors:  Masafumi Kato; Masashi Takano; Morikazu Miyamoto; Naoki Sasaki; Tomoko Goto; Ayako Suzuki; Junko Hirata; Hidenori Sasa; Hitoshi Tsuda; Kenichi Furuya
Journal:  Mol Clin Oncol       Date:  2016-08-02

5.  An allelotype analysis indicating the presence of two distinct ovarian clear-cell carcinogenic pathways: endometriosis-associated pathway vs. clear-cell adenofibroma-associated pathway.

Authors:  Sohei Yamamoto; Hitoshi Tsuda; Kozue Suzuki; Masashi Takano; Seiichi Tamai; Osamu Matsubara
Journal:  Virchows Arch       Date:  2009-08-05       Impact factor: 4.064

6.  Aberrant expression of p27(Kip1)-interacting cell-cycle regulatory proteins in ovarian clear cell carcinomas and their precursors with special consideration of two distinct multistage clear cell carcinogenetic pathways.

Authors:  Sohei Yamamoto; Hitoshi Tsuda; Kosuke Miyai; Masashi Takano; Seiichi Tamai; Osamu Matsubara
Journal:  Virchows Arch       Date:  2009-10-24       Impact factor: 4.064

7.  Pathogenesis of ovarian clear cell adenofibroma, atypical proliferative (borderline) tumor, and carcinoma: clinicopathologic features of tumors with endometriosis or adenofibromatous components support two related pathways of tumor development.

Authors:  Chengquan Zhao; Lee Shu-Fune Wu; Ross Barner
Journal:  J Cancer       Date:  2011-02-21       Impact factor: 4.207

8.  Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.

Authors:  Martin Köbel; Steve E Kalloger; Niki Boyd; Steven McKinney; Erika Mehl; Chana Palmer; Samuel Leung; Nathan J Bowen; Diana N Ionescu; Ashish Rajput; Leah M Prentice; Dianne Miller; Jennifer Santos; Kenneth Swenerton; C Blake Gilks; David Huntsman
Journal:  PLoS Med       Date:  2008-12-02       Impact factor: 11.069

9.  Clear Cell Adenocarcinoma Arising from Adenofibroma in a Patient with Endometriosis of the Ovary.

Authors:  Inju Cho; Sung-Chul Lim
Journal:  J Pathol Transl Med       Date:  2015-10-26

10.  Borderline Clear Cell Adenofibroma of the Ovary.

Authors:  Pilaiwan Kleebkaow; Apiwat Aue-Aungkul; Amornrat Temtanakitpaisan; Chumnan Kietpeerakool
Journal:  Case Rep Pathol       Date:  2017-03-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.